Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2 Tumor Vaccine in gastric/GEJ cancer
NCT05315830Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of HER2 Tumor Vaccine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoint: Incidence of adverse events at 6 months. Status: unknown.
02
Drugs
HER2 Tumor Vaccine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05315830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05315830.